- Home
- XGN vs BLRX Comparison
XGN vs BLRX Comparison
Compare XGN & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XGN
- BLRX
- Stock Information
- Founded
- XGN 2002
- BLRX 2003
- Country
- XGN United States
- BLRX Israel
- Employees
- XGN N/A
- BLRX N/A
- Industry
- XGN Medical Specialities
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- XGN Health Care
- BLRX Health Care
- Exchange
- XGN Nasdaq
- BLRX Nasdaq
- Market Cap
- XGN 49.4M
- BLRX 54.1M
- IPO Year
- XGN 2019
- BLRX 2011
- Fundamental
- Price
- XGN $2.65
- BLRX $0.49
- Analyst Decision
- XGN Buy
- BLRX Strong Buy
- Analyst Count
- XGN 1
- BLRX 2
- Target Price
- XGN $7.00
- BLRX $11.50
- AVG Volume (30 Days)
- XGN 24.1K
- BLRX 320.6K
- Earning Date
- XGN 11-11-2024
- BLRX 11-18-2024
- Dividend Yield
- XGN N/A
- BLRX N/A
- EPS Growth
- XGN N/A
- BLRX N/A
- EPS
- XGN N/A
- BLRX N/A
- Revenue
- XGN $56,660,000.00
- BLRX $17,048,000.00
- Revenue This Year
- XGN $9.98
- BLRX N/A
- Revenue Next Year
- XGN $13.63
- BLRX N/A
- P/E Ratio
- XGN N/A
- BLRX N/A
- Revenue Growth
- XGN 7.05
- BLRX N/A
- 52 Week Low
- XGN $1.30
- BLRX $0.43
- 52 Week High
- XGN $3.71
- BLRX $1.93
- Technical
- Relative Strength Index (RSI)
- XGN 39.30
- BLRX 34.05
- Support Level
- XGN $2.64
- BLRX $0.43
- Resistance Level
- XGN $3.03
- BLRX $0.56
- Average True Range (ATR)
- XGN 0.17
- BLRX 0.05
- MACD
- XGN -0.05
- BLRX -0.01
- Stochastic Oscillator
- XGN 1.67
- BLRX 23.96
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.